MHRA Approves Johnson Matthey’s Annan, UK, Site for GMP Manufacturing

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-10-05-2016
Volume 11
Issue 10

The certification follows a successful inspection by the MHRA, with no critical or major observations. The site is now ready to start production.

Johnson Matthey, a provider of pharmaceutical services, APIs, and catalyst technologies, announced on Sept. 20, 2016 that its facilities in Annan, United Kingdom, have been certified for GMP manufacturing by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Johnson Matthey acquired the Annan facility in November 2014 as part of plans to expand its Fine Chemicals Division’s large-volume capacity and address customer demand for controlled substance APIs and custom manufacturing services.

Johnson Matthey refurbished the Annan site, which is now fully equipped for GMP manufacturing. The certification follows a successful inspection by the MHRA, with no critical or major observations. With the site now ready to start production, the company will be recruiting 35 new staff across various manufacturing and operational positions.  

Johnson Matthey’s investment in the Annan facilities represents an important part of the Fine Chemicals Division’s ongoing growth strategy. The successful audit of the new site follows Johnson Matthey’s recent expansion of its Cambridge, UK, facilities and acquisition of the Pharmorphix solid form sciences business within the European Custom Pharma Solutions offering.

Source: Johnson Matthey

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Related Content